Key result
Tocilizumab linked to improved 7-day LVEF and lower mortality versus Remdesivir in COVID-19 myocarditis.
Why the study?
Myocarditis is a fatal and morbid complication of COVID-19, and the effects of Remdesivir and Tocilizumab on COVID-19 myocarditis outcomes require assessment.
Does tocilizumab or remdesivir improve cardiac function and mortality in patients with COVID-19 myocarditis?
Cohort
Does tocilizumab or remdesivir improve cardiac function and mortality in patients with COVID-19 myocarditis?
Tocilizumab may improve cardiac function and reduce mortality in early COVID-19 myocarditis by modulating miR-21 expression, whereas remdesivir may be associated with worsened cardiac outcomes.
Answers are grounded in this paper and cite their sources.
Tocilizumab was associated with better ejection fraction and lower mortality than remdesivir in this COVID-19 myocarditis cohort; leaves open whether it warrants prospective confirmation before practice change.
BACKGROUND: Myocarditis is now one of the most fatal and morbid complications of COVID-19. Many scientists have recently concentrated on this problem. OBJECTIVES: This study assessed the effects of Remdesivir (RMS) and Tocilizumab (TCZ) in COVID-19 myocarditis. DESIGN: Observational, cohort study. METHODS: Patients with COVID-19 myocarditis were enrolled in the study and divided into three groups, TCZ-treated, RMS-treated, and Dexamethasone-treated patients. After 7 days of treatment, patients were reassessed for improvement. RESULTS: TCZ significantly improved patients' ejection fraction in 7 days, but it had limited efficacy. RMS improved inflammatory characteristics of the disease, but RMS-treated patients showed exacerbated cardiac function over 7 days, and the mortality rate with RMS was higher than TCZ. TCZ protects the heart by decreasing the miR-21 expression rate. CONCLUSION: Using Tocilizumab in early diagnosed COVID-19 myocarditis patients can save their cardiac function after hospitalization and decrease the mortality rate. miR-21 level determines the outcome and responsiveness of COVID-19 myocarditis to treatment.
No takes yet. Share an insight, caveat, or question.
Heydari et al. (2023) conducted a cohort in COVID-19 myocarditis. Tocilizumab vs. Remdesivir and Dexamethasone was evaluated on Improvement in cardiac function and mortality. Tocilizumab improved ejection fraction at 7 days and was associated with lower mortality compared to Remdesivir in patients with COVID-19 myocarditis.
Synapse has enriched 10 related papers. Consider them for comparative context: